Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

12.5%

8 terminated/withdrawn out of 64 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

53%

34 trials in Phase 3/4

Results Transparency

77%

37 of 48 completed trials have results

Key Signals

2 recruiting37 with results6 terminated

Enrollment Performance

Analytics

Phase 3

20(32.3%)

Phase 2

19(30.6%)

Phase 4

14(22.6%)

Phase 1

7(11.3%)

Early Phase 1

1(1.6%)

N/A

1(1.6%)

62Total

Phase 3(20)

Phase 2(19)

Phase 4(14)

Phase 1(7)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (64)

Showing 20 of 64 trials

NCT02682511Phase 2Active Not Recruiting

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Role: lead

NCT03340675Phase 2Completed

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

Role: lead

NCT05571059Phase 2Recruiting

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Role: lead

NCT07387666Early Phase 1Not Yet Recruiting

Imaging Acetadote Metabolism in Glioblastoma

Role: collaborator

NCT06119061Phase 4Recruiting

Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage

Role: collaborator

NCT03962855Phase 2Completed

Thromboxane Receptor Antagonist to Improve Endothelial Function

Role: collaborator

NCT00780962Phase 2Completed

N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients

Role: collaborator

NCT03028350Phase 2Completed

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

Role: lead

NCT03694249Phase 2Active Not Recruiting

Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

Role: collaborator

NCT02013141Phase 1Terminated

Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)

Role: lead

NCT01334957Phase 4Completed

Surgical Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen

Role: lead

NCT01334944Phase 4Completed

Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen

Role: lead

NCT03611010Phase 2Completed

Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients

Role: lead

NCT02802228Phase 2Completed

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

Role: lead

NCT02583399Phase 4Completed

Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients

Role: lead

NCT01130324Withdrawn

VIBATIV Pregnancy Registry

Role: lead

NCT02208063Phase 3Terminated

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

Role: lead

NCT00062647Phase 2Completed

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

Role: lead

NCT00107952Phase 3Completed

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

Role: lead

NCT00091819Phase 3Completed

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

Role: lead